Wegovy claims soared 91% in 2024 as insurers weigh coverage limits and rising plan costs
Wegovy drives 91% spike in Canadian drug claims while Zepbound outperforms in US clinical trial
Canadian Drug Insurance Pooling Corporation members saved over $946 million in out-of-pocket drug costs through extended policy plans in 2023
"The price thing is a red herring," says former Patented Medicine Prices Review Board head, calling out delays in drug approvals
Novo Nordisk faces pressure from Eli Lilly, but its latest earnings and sales outlook push shares higher
Founder of PAFA highlights how they're helping to streamline the PA process for payers
